Do you own shares of ViroPharma Incorporated (NASDAQ GS: VPHM)?
Did you purchase any of your shares prior to November 11, 2013?
Do you think the proposed buyout price is too low?
Do you want to discuss your rights?
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of ViroPharma Incorporated (“ViroPharma” or the “Company”) (NASDAQ GS: VPHM) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Shire plc (“Shire”) (NASDAQ GS: SHPG) in a transaction valued at approximately $4.2 billion. Click here to learn more: http://www.rigrodskylong.com/investigations/viropharma-incorporated-vphm. Under the terms of the agreement, public shareholders of ViroPharma will receive $50.00 per share in cash for each share of ViroPharma they own. The investigation concerns whether ViroPharma’s board of directors failed to adequately shop the Company and obtain the best possible value for ViroPharma’s shareholders before entering into an agreement with Shire. If you own the common stock of ViroPharma and purchased your shares before November 11, 2013, if you have information or would like to learn more about these claims, or if you wish to discuss these matters or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 825 East Gate Boulevard, Suite 300, Garden City, New York 11530, by telephone at (888) 969-4242; by e-mail to email@example.com, or at: http://www.rigrodskylong.com/investigations/viropharma-incorporated-vphm. Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities class, derivative and direct actions, shareholder rights litigation and corporate governance litigation, on behalf of shareholders in states and federal courts throughout the United States. Attorney advertising. Prior results do not guarantee a similar outcome.
Irish pharmaceuticals company Shire said on Friday it had arranged to hand its Dermagraft skin substitute to Organogenesis and take a $650 million loss on the disposal, which unwinds a major part of an acquisition it made less than three years ago.